Mihaly Hajos, PharmD, PhD
Professor AdjunctCards
About
Research
Overview
Medical Research Interests
Mental Disorders
Publications
2025
Alpha rhythm and Alzheimer’s disease: Has Hans Berger’s dream come true?
Babiloni C, Arakaki X, Baez S, Barry R, Benussi A, Blinowska K, Bonanni L, Borroni B, Bayard J, Bruno G, Cacciotti A, Carducci F, Carino J, Carpi M, Conte A, Cruzat J, D'Antonio F, Della Penna S, Del Percio C, De Sanctis P, Escudero J, Fabbrini G, Farina F, Fraga F, Fuhr P, Gschwandtner U, Güntekin B, Guo Y, Hajos M, Hallett M, Hampel H, Hanoğlu L, Haraldsen I, Hassan M, Hatlestad-Hall C, Horváth A, Ibanez A, Infarinato F, Jaramillo-Jimenez A, Jeong J, Jiang Y, Kamiński M, Koch G, Kumar S, Leodori G, Li G, Lizio R, Lopez S, Ferri R, Maestú F, Marra C, Marzetti L, McGeown W, Miraglia F, Moguilner S, Moretti D, Mushtaq F, Noce G, Nucci L, Ochoa J, Onorati P, Padovani A, Pappalettera C, Parra M, Pardini M, Pascual-Marqui R, Paulus W, Pizzella V, Prado P, Rauchs G, Ritter P, Salvatore M, Santamaria-García H, Schirner M, Soricelli A, Taylor J, Tankisi H, Tecchio F, Teipel S, Kodamullil A, Triggiani A, Valdes-Sosa M, Valdes-Sosa P, Vecchio F, Vossel K, Yao D, Yener G, Ziemann U, Kamondi A. Alpha rhythm and Alzheimer’s disease: Has Hans Berger’s dream come true? Clinical Neurophysiology 2025, 172: 33-50. PMID: 39978053, DOI: 10.1016/j.clinph.2025.02.256.Peer-Reviewed Original ResearchConceptsPathological agingAlzheimer's diseaseExpert panelAlpha rhythmAD patient’s qualityQuality of lifeAging-Alzheimer's AssociationCognitive impairmentCognitive declineClinical workupNeuroscience SocietyCortical circuitsAD patientsUS National InstitutesOlder adultsRoutine useSenile dementiaDecades of researchPatients' qualityClinical guidelinesOscillatory synchronizationCause of dementiaClinical applicationNIA-AADementiaCSF proteomics reveals changes in myelin and synaptic biology after Spectris treatment
Hajós M, Pandey K, Singer A, Duong D, Bitarafan S, Shpokayte M, Malchano Z, Kern R, Lah J, Levey A, Seyfried N. CSF proteomics reveals changes in myelin and synaptic biology after Spectris treatment. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2025, 11: e70051. PMID: 39935616, PMCID: PMC11812123, DOI: 10.1002/trc2.70051.Peer-Reviewed Original ResearchCellular lipid transportLipid transportWeeks of treatmentProteomic changesAlzheimer's diseaseCerebrospinal fluidGamma oscillationsTandem mass tag-mass spectrometryNeuroimmune functionDifferential expression analysisMyelin preservationUnbiased proteomic analysisBiological pathway analysisTreatment of ADSynaptic biologyAffected proteinsProteome modulationPhosphatidylcholine biosynthesisReduced brain volumeCSF proteome changesProtein networkSensory‐evoked gamma oscillationsExpression analysisBiochemical pathwaysBiological pathways
2024
OVERTURE Phase 2 Study time‐savings analysis using composite measures of function and cognition
Kern R, Haaland B, Nicodemus‐Johnson J, Dickson S, Kuang Z, Houser C, Hajos M, Vaughan B, Hendrix S. OVERTURE Phase 2 Study time‐savings analysis using composite measures of function and cognition. Alzheimer's & Dementia 2024, 20: e094669. PMCID: PMC11712459, DOI: 10.1002/alz.094669.Peer-Reviewed Original ResearchRandomized controlled trialsADCS-ADLSham treatmentMeasures of functionIndividual patient changesComposite measureMild-moderate Alzheimer's diseaseAt-homeMild-moderate ADTreatment effectsBaseline measurementsAlzheimer's diseaseEstimated time savingsPatients changesOne-hourMMSEPost-hocActive treatmentOutcomesTrialsBaselineAdverse eventsADLOVERTURE Phase 2 Clinical Trial MRI Outcomes Demonstrate Consistent Treatment Benefits in Subgroup Analysis
Kern R, Kuang C, Seshagiri C, Konisky A, Galley A, Boasso A, Hempel E, Malchano Z, Vaughan B, Cimenser A, Da X, Shpokayte M, Hajos M. OVERTURE Phase 2 Clinical Trial MRI Outcomes Demonstrate Consistent Treatment Benefits in Subgroup Analysis. Alzheimer's & Dementia 2024, 20: e085091. PMCID: PMC11714597, DOI: 10.1002/alz.085091.Peer-Reviewed Original ResearchRandomized controlled trialsAPOE4 carrier statusBaseline subgroupsMild-moderate Alzheimer's diseasePhase 2 clinical trialIndicators of neurodegenerationBrain atrophyBrain volume outcomesBaseline ageBrain volume lossWhole brain volume lossCarrier statusWBVMagnetic resonance imagingAlzheimer's diseaseBaseline covariatesMonth 6Subgroup analysisAt-homeParticipantsClinical trialsTreatment outcomesActive treatmentOne-hourSham treatmentOVERTURE Phase 2 MRI Analysis Demonstrates Reduced Corpus Callosum Atrophy in Alzheimer's Disease
Da X, Hempel E, Hajos M, Kern R, Cimenser A. OVERTURE Phase 2 MRI Analysis Demonstrates Reduced Corpus Callosum Atrophy in Alzheimer's Disease. Alzheimer's & Dementia 2024, 20: e085446. PMCID: PMC11714734, DOI: 10.1002/alz.085446.Peer-Reviewed Original ResearchMagnetic resonance imagingMonth 3Midsagittal planeDiffusion tensor imagingPhase 3 clinical trialsRegional structural alterationsCorpus callosumT1w MRI imagesMonths of treatmentCommissural white matter tractsCorpus callosum atrophyWhite matter atrophyAlzheimer's diseaseSensory stimulationMonth 6CC atrophyClinical trialsSham groupWhite matter tractsGamma frequenciesVisual stimulationResonance imagingMechanistic Insights of Gamma Sensory Stimulation: CSF Proteomic Analyses Reveal Changes in Myelin and Synaptic Proteins
Shpokayte M, Pandey K, Singer A, Doung D, Lah J, Levey A, Seyfried N, Malchano Z, Kern R, Hajos M. Mechanistic Insights of Gamma Sensory Stimulation: CSF Proteomic Analyses Reveal Changes in Myelin and Synaptic Proteins. Alzheimer's & Dementia 2024, 20: e087390. PMCID: PMC11715388, DOI: 10.1002/alz.087390.Peer-Reviewed Original ResearchCell surface receptorsAlzheimer's diseaseSurface receptorsCo-expression modulesDifferential expression analysisAD-related pathologyContext of ADProteome databasePost-synaptic densityProteomic analysisExpression analysisSynaptic proteinsCerebrospinal fluid proteomeCerebrospinal fluidProteinSignificance thresholdMyelin-related proteinsSynaptic regulationMechanism of actionSensory stimulationCellsPrecursor cellsRegulationCerebrospinal fluid samplesCerebrospinal fluid proteinSpectris™ treatment preserves corpus callosum structure in Alzheimer's disease
Da X, Hempel E, Brickman A, Hajós M, Kern R, Cimenser A. Spectris™ treatment preserves corpus callosum structure in Alzheimer's disease. Frontiers In Neurology 2024, 15: 1452930. PMID: 39479005, PMCID: PMC11522122, DOI: 10.3389/fneur.2024.1452930.Peer-Reviewed Original ResearchParallel electrophysiological abnormalities due to COVID‐19 infection and to Alzheimer's disease and related dementia
Jiang Y, Neal J, Sompol P, Yener G, Arakaki X, Norris C, Farina F, Ibanez A, Lopez S, Al‐Ezzi A, Kavcic V, Güntekin B, Babiloni C, Hajós M. Parallel electrophysiological abnormalities due to COVID‐19 infection and to Alzheimer's disease and related dementia. Alzheimer's & Dementia 2024, 20: 7296-7319. PMID: 39206795, PMCID: PMC11485397, DOI: 10.1002/alz.14089.Peer-Reviewed Original ResearchCOVID-19 patientsEEG abnormalitiesNeurophysiological abnormalitiesMild cognitive impairmentCognitive deficitsBrain activityAstrocyte reactivityPredicting long-term outcomesCognitive impairmentLong-term outcomesSlowing of EEGCognitive declineEfficacy of therapeutic interventionsIntrinsic brain activityLong COVIDElectrophysiological brain activityEEG slowingNeurological complicationsEpileptiform activityEEG monitoringEarly stages of neurodegenerative diseasesCognitive decline riskNeurovascular injuryLong COVID-19Acute phaseCognito’s non-invasive medical device demonstrates durable effects on activities of daily living through OVERTURE open-label extension study. (N2.002)
Kern R, Kuang C, Hajos M, Konisky A, Boasso A, Hempel E, Vaughan B, Seshagiri C, Malchano Z, Hendrix S, Saikali K, Massey J, Arjunji R. Cognito’s non-invasive medical device demonstrates durable effects on activities of daily living through OVERTURE open-label extension study. (N2.002). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000205670.Peer-Reviewed Original ResearchSafety, tolerability, and efficacy estimate of evoked gamma oscillation in mild to moderate Alzheimer’s disease
Hajós M, Boasso A, Hempel E, Shpokayte M, Konisky A, Seshagiri C, Fomenko V, Kwan K, Nicodemus-Johnson J, Hendrix S, Vaughan B, Kern R, Megerian J, Malchano Z. Safety, tolerability, and efficacy estimate of evoked gamma oscillation in mild to moderate Alzheimer’s disease. Frontiers In Neurology 2024, 15: 1343588. PMID: 38515445, PMCID: PMC10957179, DOI: 10.3389/fneur.2024.1343588.Peer-Reviewed Original ResearchAssessment of adverse eventsMild to moderate ADGamma oscillationsModerate ADAmyloid-related imaging abnormalitiesAlzheimer's diseaseMild-to-moderate Alzheimer's diseaseSecondary clinical outcome measuresTherapy systemPrimary outcome measureHigher adherence ratesWhole-brain volumeClinical outcome measuresSecondary outcome measuresModerate Alzheimer's diseaseDisease-modifying effectsBaseline MMSE scoreStudy discontinuationExperimental AD modelsWell-toleratedEfficacy outcomesClinical benefitAdverse eventsDaily treatmentClinical criteria